Search Results - "Freimer ML"

Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review.

Authors: Lewis, Richard A. Cornblath, David R. Hartung, Hans‐Peter et al.

Source: Journal of the Peripheral Nervous System. Sep2020, Vol. 25 Issue 3, p230-237. 8p.

Hirayama Disease: Latest Insights into an Intriguing Disorder.

Authors: Baskar, Dipti Nalini, Atchayaram Vengalil, Seena

Source: Annals of Indian Academy of Neurology. Mar/Apr2026, Vol. 29 Issue 2, p141-149. 9p.

Efficacy and safety of zilucoplan in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the phase III randomized RAISE study.

Authors: Utsugisawa, Kimiaki Deguchi, Kazushi Konno, Shingo et al.

Source: Clinical & Experimental Neuroimmunology. Feb2024, Vol. 15 Issue 1, p45-54. 10p.

Experiences of Immunoglobulin Therapy for Those with a Confirmed Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy: A Mixed-Methods Study with a Qualitative Patient Perspective Focus.

Authors: Hubsch, Alphonse Cashmore, Sarah-Jane Mallick, Rajiv et al.

Source: Patient Preference & Adherence. Dec2025, Vol. 19, p3999-4019. 21p.

Targeting NF-kappaB-inducing kinase shapes B-cell homeostasis in myasthenia gravis.

Authors: Huang, Xiaoyu Zhang, Zhouao Wang, Zhouyi et al.

Source: Journal of Neuroinflammation. 1/24/2025, Vol. 22 Issue 1, p1-16. 16p.

Surgical Management of Hirayama Disease: A Rare Entity With Unusual Clinical Features.

Authors: Cheekatla, Suresh Anudeep, Peddineni

Source: Indian Spine Journal. Jan-Jun2025, Vol. 8 Issue 1, p85-90. 6p.

Therapeutic strategies targeting complement in myasthenia gravis patients.

Authors: Wang Y Nao J Duan Y et al.

Source: Journal of neurology [J Neurol] 2025 Jul 02; Vol. 272 (8), pp. 489. Date of Electronic Publication: 2025 Jul 02.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0423161 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-1459 (Electronic) Linking ISSN: 03405354 NLM ISO Abbreviation: J Neurol Subsets: MEDLINE

The link between the sphingolipid rheostat and obstructive sleep apnea.

Authors: Horváth, Péter Büdi, Lilla Hammer, Dániel et al.

Source: Scientific Reports. 5/11/2023, Vol. 13 Issue 1, p1-8. 8p.

Pharmacological and speech-language pathology management of dysphagia in patients with myasthenia gravis.

Authors: Ferrara F De Berardinis F

Source: Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2026 Mar; Vol. 399 (6), pp. 9245-9257. Date of Electronic Publication: 2026 Jan 12.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0326264 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1912 (Electronic) Linking ISSN: 00281298 NLM ISO Abbreviation: Naunyn Schmiedebergs Arch Pharmacol Subsets: MEDLINE

Pharmaco-therapeutic modulation of the Glo1-Nrf2-RAGE functional network in chronic inflammation: polyphenols in the context of current anti-inflammatory therapy.

Authors: Ali S Akhtar MS Amin A et al.

Source: Inflammopharmacology [Inflammopharmacology] 2026 Jun; Vol. 34 (6), pp. 3873-3886. Date of Electronic Publication: 2026 Apr 29.

Publication Type: Journal Article; Review

Journal Info: Publisher: Birkhäuser Country of Publication: Switzerland NLM ID: 9112626 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1568-5608 (Electronic) Linking ISSN: 09254692 NLM ISO Abbreviation: Inflammopharmacology Subsets: MEDLINE

A mild course of COVID-19 infection in a generalized Myasthenia gravis patient under eculizumab treatment.

Authors: Alis, Ceren Emre, Dogukan Hazar Karaali Savrun, Feray et al.

Source: Neurological Sciences. Sep2022, Vol. 43 Issue 9, p5185-5187. 3p.

Iranian Consensus Recommendations for Treatment of Myasthenia Gravis.

Authors: Nafissi, Shahriar Okhovat, Ali Asghar Sinaei, Farnaz et al.

Source: Archives of Iranian Medicine (AIM). Jan2022, Vol. 25 Issue 1, p37-49. 13p.

Changes in axonal and clinical function during intravenous and subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.

Authors: Hansen, Peter N. Mohammed, Abdullahi A. Markvardsen, Lars K. et al.

Source: Journal of the Peripheral Nervous System. Sep2023, Vol. 28 Issue 3, p425-435. 11p.

Intravenous Immunoglobulin Treatment Patterns and Outcomes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims Database Analysis.

Authors: Anderson-Smits, Colin Ritchey, Mary E. Huang, Zhongwen et al.

Source: Neurology & Therapy. Aug2023, Vol. 12 Issue 4, p1119-1132. 14p.

Efficacy and safety of immunosuppressants and immunomodulators in juvenile myasthenia gravis: a systematic review and meta-analysis.

Authors: Zhong X Xie Y Li Y et al.

Source: Journal of translational medicine [J Transl Med] 2026 Mar 02; Vol. 24 (1). Date of Electronic Publication: 2026 Mar 02.

Publication Type: Journal Article; Systematic Review; Meta-Analysis; Review

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-5876 (Electronic) Linking ISSN: 14795876 NLM ISO Abbreviation: J Transl Med Subsets: MEDLINE

Inventory Commitment and Monetary Compensation Under Competition.

Authors: Lei, Junfei Zhang, Fuqiang Zhang, Renyu et al.

Source: Manufacturing & Service Operations Management (M&SOM) (INFORMS). Nov/Dec2023, Vol. 25 Issue 6, p2142-2159. 18p.

Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy.

Authors: Fichtner, Miriam L. Hoehn, Kenneth B. Ford, Easton E. et al.

Source: Acta Neuropathologica Communications. 10/28/2022, Vol. 10 Issue 1, p1-16. 16p.

Efficacy and safety of immunosuppressants and monoclonal antibodies in adults with myasthenia gravis: a systematic review and network meta-analysis.

Authors: Gu, Jian Qiao, Yue Huang, Rui et al.

Source: Journal of Translational Medicine. 10/21/2024, Vol. 22 Issue 1, p1-13. 13p.

Myasthenia gravis complement activity is independent of autoantibody titer and disease severity.

Authors: Fichtner, Miriam L. Hoarty, Michelle D. Vadysirisack, Douangsone D. et al.

Source: PLoS ONE. 3/15/2022, Vol. 17 Issue 3, p1-11. 11p.

Progressive muscle weakness and amyotrophy during pregnancy as the first manifestation of systemic lupus erythematosus: A case report and review of literature.

Authors: Wang, Liu Wang, Dan Ruan, Yuyi et al.

Source: Science Progress. 12/23/2021, p1-21. 21p.